Catalog No.
DHH28805
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q16552
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
AG1-25, CAS: 1796570-08-5
Clone ID
Netakimab
Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis, PMID: 33977094
Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study, PMID: 34237556
Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta-analysis, PMID: 33768576
Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials, PMID: 33432451
Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial, PMID: 34060012
Emerging systemic drugs in the treatment of plaque psoriasis, PMID: 32192366
IL-17 inhibition in axial spondyloarthritis: current and future perspectives, PMID: 30957574
Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19), PMID: 34346869
Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules, PMID: 34239295
Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults, PMID: 31025924
State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis, PMID: 31212119
Efficacy and Safety of Interleukin-17 and Janus Kinase Inhibitors in Ankylosing Spondylitis: A Systematic Review and Network Meta-Analysis., PMID:40010328
Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review., PMID:39982633
Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders., PMID:39875232
Real-World Retention Rate, Effectiveness, and Safety of Netakimab in the Treatment of Patients with Ankylosing Spondylitis: First Year Results of the LIBRA Post-Registration Safety Study., PMID:39196530
Course of Uveitis in Patients with Ankylosing Spondylitis during the Interleukin17 Inhibitors Therapy., PMID:38861150
[Current treatment for spondyloarthritis: focus on netakimab. A review]., PMID:38829817
[Real-world experience with netakimab in the treatment of spondyloarthritis]., PMID:38785057
NEUROPROTECTIVE AND ANTIOXIDANT POTENTIAL OF MONTELUKAST-ACETYLCYSTEINE COMBINATION THERAPY FOR BRAIN PROTECTION IN PATIENTS WITH COVID-19 INDUCED PNEUMONIA., PMID:37042600
Two Epitope Regions Revealed in the Complex of IL-17A and Anti-IL-17A VHH Domain., PMID:36499233
Biological treatment for erythrodermic psoriasis., PMID:36154361
Response to netakimab in radiographic axial spondyloarthritis patients with different baseline C-reactive protein, sacroiliitis evaluated by MRI and peripheral joint involvement status: a post-hoc analysis of the ASTERA study., PMID:36062743
Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study., PMID:36001576
Immune-related adverse events (irAEs) in ankylosing spondylitis (AS) patients treated with interleukin (IL)-17 inhibitors: a systematic review and meta-analysis., PMID:35188599
Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19)., PMID:34346869
Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules., PMID:34239295
Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study., PMID:34237556
Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial., PMID:34060012
Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis., PMID:33977094
Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta-analysis., PMID:33768576
Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials., PMID:33432451
Emerging systemic drugs in the treatment of plaque psoriasis., PMID:32192366
State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis., PMID:31212119
Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults., PMID:31025924
IL-17 inhibition in axial spondyloarthritis: current and future perspectives., PMID:30957574
For research use only. Not for human or drug use.
